Prevalence of the fibrinogen β-chain, angiotensin-converting enzyme and plasminogen activator inhibitor-1 polymorphisms in Costa Rican young adults with thrombotic disease

被引:1
|
作者
Hidalgo, Andrea [1 ]
Salazar-Sanchez, Lizbeth [1 ]
Cartin, Mayra [2 ]
Mendez, Max [1 ]
Arauz, Jorge [3 ]
Parajeles, Alexander [4 ]
机构
[1] Univ Costa Rica, CIHATA, Hosp San Juan de Dios, San Jose 106341000, Costa Rica
[2] Univ Costa Rica, Publ Healthy Sch, San Jose 106341000, Costa Rica
[3] San Juan de Dios Hosp, Dept Cardiol, San Jose, Costa Rica
[4] San Juan de Dios Hosp, Dept Neurol, San Jose, Costa Rica
关键词
polymorphisms; fibrinogen; plasminogen activator inhibitor-1; thrombosis; angiotensin-converting enzyme; CORONARY-ARTERY-DISEASE; INSERTION DELETION POLYMORPHISM; PAI-1 PROMOTER POLYMORPHISM; MYOCARDIAL-INFARCTION; GENE POLYMORPHISM; CARDIOVASCULAR-DISEASE; CEREBROVASCULAR-DISEASE; HEART-DISEASE; RISK; REGION;
D O I
10.1002/cbf.1655
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Thrombotic disease is a multifactorial condition that involves both classical and genetic risk factors. We studied the association between the classical risk factors of hypertension and smoking, and polymorphisms on the genes of the angiotensin-converting enzyme (ACE), the p-chain of fibrinogen (FG), and the plasminogen activator inhibitor-1 (PAI-1) in patients with venous and arterial thrombosis. The present investigation is a retrospective case-control study. A total of 340 participants were analyzed, including 162 patients and 178 healthy controls. Hypertension and smoking showed a significant association with thrombotic disease (p < 0.05) but FG level was found significant risk factor only for the venous thrombosis (VT) group (p < 0.04). Significant differences between thrombotic groups were found for the studied polymorphisms of PAI-1 (p < 0.0014). but for both FG beta-chain gene polymorphisms, none of the molecular analyses showed a positive sample for any mutating allele (p > 0.05). For the ACE polymorphism, the I allele present a protective effect in the general thrombotic group. This is one of the first reports in a Latin-American population dealing with these molecular markers and thrombotic diseases. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:367 / 373
页数:7
相关论文
共 50 条
  • [41] Glutathione S-transferase (M1 and T1) and angiotensin-converting enzyme gene polymorphisms and chronic kidney disease in Bangladeshi population
    Shawon, Jakaria
    Rahman, Md Mostafijur
    Nahar, Zabun
    Kabir, Yearul
    META GENE, 2021, 30
  • [42] Comparison of Plasminogen Activator Inhibitor-1, Tissue Type Plasminogen Activator Antigen, Fibrinogen, and D-Dimer Levels in Various Age Decades in Patients With Type 2 Diabetes Mellitus and Stable Coronary Artery Disease (from the BARI 2D Trial)
    McBane, Robert D., II
    Hardison, Regina M.
    Sobel, Burton E.
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (01) : 17 - 24
  • [43] Left ventricular size, mass and function in relation to angiotensin-converting enzyme gene and angiotensin-II type 1 receptor gene polymorphisms in patients with coronary artery disease
    Gruchala, M
    Ciecwierz, D
    Ochman, K
    Wasag, B
    Koprowski, A
    Wojtowicz, A
    Dubaniewicz, W
    Targonski, R
    Sobiczewski, W
    Grzybowski, A
    Romanowski, P
    Limon, J
    Rynkiewicz, A
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (04) : 522 - 528
  • [44] Prevalence of coagulation factor XIII and plasminogen activator inhibitor-1 gene polymorphisms among Egyptian women suffering from unexplained primary recurrent miscarriage
    Elmahgoub, Iman Rifaat
    Afify, Reham Abdelaleem
    Aal, Asmaa Ahmed Abdel
    EI-Sherbiny, Walid Sayed
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2014, 103 : 18 - 22
  • [45] Effects of aliskiren on the fibrinolytic system in patients with coronary artery disease receiving angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker
    Ken Ishibashi
    Satoshi Kurisu
    Yasuko Kato
    Naoya Mitsuba
    Yoshihiro Dohi
    Kenji Nishioka
    Yasuki Kihara
    Heart and Vessels, 2013, 28 : 7 - 11
  • [46] Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination
    Tsikouris, James P.
    Cox, Craig D.
    Simoni, Jan S.
    Seifert, Charles F.
    Peek, Miranda C.
    Meyerrose, Gary E.
    CORONARY ARTERY DISEASE, 2006, 17 (05) : 439 - 445
  • [47] Angiotensin-converting enzyme 1 gene polymorphisms in patients with systemic sclerosis-associated interstitial lung disease: a single centre retrospective observational study
    Karanovic, Boris
    Baresic, Marko
    Merkler Sorgic, Ana
    Anic, Branimir
    RHEUMATOLOGY INTERNATIONAL, 2023, 43 (12) : 2303 - 2309
  • [48] Angiotensin-converting enzyme 1 gene polymorphisms in patients with systemic sclerosis-associated interstitial lung disease: a single centre retrospective observational study
    Boris Karanović
    Marko Barešić
    Ana Merkler Šorgić
    Branimir Anić
    Rheumatology International, 2023, 43 : 2303 - 2309
  • [49] Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in Czech male Caucasians
    Benes, P
    Muzík, J
    Benedík, J
    Frélich, M
    Elbl, L
    Vasku, A
    Znojil, V
    Vácha, J
    MOLECULAR GENETICS AND METABOLISM, 2000, 69 (02) : 137 - 143
  • [50] Plasminogen activator inhibitor-1 (PAI-1), toll-like receptor 4 (TLR4), factor II (FII), FXIII and fibrinogen polymorphisms are not associated with the prevalence of sudden death due to ventricular fibrillation during myocardial infarction
    Elmas, Elif
    Ahmad-Nejad, Parviz
    Weiss, Christel
    Neumaier, Michael
    Borggrefe, Martin
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2008, 46 (09) : 1329 - 1331